Tuesday, March 17, 2009
$40 Million Qui Tam Settlement Between Healthways and U.S. Government
Healthways has agreed to a $40 million settlement with the U.S. Government resulting from a qui tam lawsuit brought by a former employee. The company was accused of paying doctors to refer patients to its Diabetes Treatment Centers. The settlement is, “not an admission of wrongdoing”, according to CEO Ben Leedle. Healthways concluded that, “the proposed settlement is in the best interests of the company and its shareholders.”
Click here to read the full article on Healthways and its $40 million qui tam settlement
Posted by Quitam Help Admin on 03/17 at 09:00 AM
•
Permalink
Friday, March 13, 2009
New Whistleblower Lawsuit Against Amgen, Inc.
A whistleblower has filed a lawsuit against the biotechnology company Amgen, Inc. for allegedly marketing the drugs Enbrel and Aranesp for illegal off-label use. The drugs are approved to treat rheumatoid arthritis and anemia respectively. Although physicians are allowed to prescribe medications for off-label use, it is illegal for drug manufacturers to market drugs for treatments that are not FDA approved.
Click here to read the full article about the whistleblower lawsuit against Amgen.
Posted by Quitam Help Admin on 03/13 at 03:27 PM
•
Permalink
Tuesday, March 03, 2009
Whistle is Blown on Drug Companies Scios and Johnson & Johnson for Medicare Fraud
The U.S. Justice Department announced it will join two whistleblower lawsuits against drug makers Scios and Johnson & Johnson Inc. The companies allegedly marketed drugs for use not approved by the FDA and collected hundreds of millions of dollars in reimbursements through Medicare.
Click here for the full article, “Feds Join Lawsuit Alleging Natrecor was Illegally Marketed"
Posted by Quitam Help Admin on 03/03 at 10:09 AM
•
Permalink
Drug Company Targeted for Illegal Marketing of Celexa and Lexapro
A complaint against a New York pharmaceutical company was unsealed last Wednesday for allegedly marketing the drugs Celexa and Lexapro for unapproved pediatric use and for paying doctors to prescribe the drug through illegal kickbacks. Forest Laboratories Inc. is charged with influencing doctors with cash payments disguised as grants. The company was prohibited from promoting the drugs for pediatric use by the FDA, which found neither drug to be effective and possibly dangerous in a double-blind, placebo-controlled pediatric trial.
Click here to read the full article, “United States Files Complaint Against Forest Laboratories for Allegedly Violating the False Claims Act."
Posted by Quitam Help Admin on 03/03 at 10:06 AM
•
Permalink
Page 1 of 1 pages
Printer Friendly Page
